foxo4-dri senolytic human trial 2024 2025 10mg vial - Description Peptide Inhibitors Targeting FOXO4-p53 Interactions
Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry Class II senolytics inhibit survival pathways elicited by senescent Download Scientific Diagram Senescent cells as a target for anti aging interventions: From senolytics to immune therapies PMC Frontiers FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway
Pay in 4 interest-free payments of $7.42 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23


